Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Ablynx N.V.
DescriptionTrivalent bispecific Nanobody against IL-17A and IL-17F
Molecular Target Interleukin-17A (IL-17A) ; Interleukin-17F (IL-17F)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I/II
Standard IndicationPsoriasis
Indication DetailsTreat moderate to severe psoriasis
Regulatory Designation
PartnerMerck KGaA

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today